MTOR and neoplasm: Consequently, mTOR inhibitors such as rapamycin (sirolimus) can effectively reduce glycolysis, immunosuppressive activity, and the percentage of tumor‐infiltrating M‐MDSCs in tumor‐bearing mice [13, 200].